Loading...
XNAS
SERA
Market cap104mUSD
Jul 11, Last price  
2.84USD
1D
2.90%
1Q
-12.62%
IPO
-74.18%
Name

Sera Prognostics Inc

Chart & Performance

D1W1MN
XNAS:SERA chart
No data to show
P/E
P/S
1,353.79
EPS
Div Yield, %
Shrs. gr., 5y
1.55%
Rev. gr., 5y
16.42%
Revenues
77k
-74.84%
36,00025,00082,000268,000306,00077,000
Net income
-33m
L-9.23%
-20,439,000-21,607,000-36,228,000-44,247,000-36,242,000-32,898,000
CFO
-14m
L-47.81%
-19,324,000-16,868,000-31,636,000-34,610,000-27,188,000-14,189,000

Profile

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
IPO date
Jul 15, 2021
Employees
87
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
77
-74.84%
306
14.18%
268
226.83%
Cost of revenue
36,712
40,127
45,920
Unusual Expense (Income)
NOPBT
(36,635)
(39,821)
(45,652)
NOPBT Margin
Operating Taxes
61
Tax Rate
NOPAT
(36,635)
(39,821)
(45,713)
Net income
(32,898)
-9.23%
(36,242)
-18.09%
(44,247)
22.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
406
1,218
308
BB yield
-0.15%
-0.65%
-0.79%
Debt
Debt current
194
1,018
464
Long-term debt
842
2,698
4,160
Deferred revenue
Other long-term liabilities
Net debt
(45,200)
(76,204)
(99,409)
Cash flow
Cash from operating activities
(14,189)
(27,188)
(34,610)
CAPEX
(56)
(128)
(791)
Cash from investing activities
11,743
438
5,551
Cash from financing activities
2,609
752
5
FCF
(34,695)
(39,941)
(46,999)
Balance
Cash
46,236
49,079
82,704
Long term investments
30,841
21,329
Excess cash
46,232
79,905
104,020
Stockholders' equity
(279,731)
(246,908)
(211,632)
Invested Capital
327,730
318,924
312,887
ROIC
ROCE
EV
Common stock shares outstanding
33,157
31,201
30,943
Price
8.14
36.12%
5.98
374.60%
1.26
-81.66%
Market cap
269,897
44.66%
186,580
378.55%
38,989
-81.56%
EV
224,697
110,376
(60,420)
EBITDA
(35,802)
(38,921)
(44,896)
EV/EBITDA
1.35
Interest
28
55
61
Interest/NOPBT